发现了一种ALK降解剂,用于拉提尼布耐药化合物突变
Fei Gao1, Zhenhua Wu1, Anqi Lin2
1State Key Laboratory of Cellular Stress Biology, School of Life Sciences, Faculty of Medicine and Life Sciences, Xiamen University, Xiamen, 361102, China; State-province Joint Engineering Laboratory of Targeted Drugs from Natural Products, Xiamen University, Xiamen, 361102, China; Cancer Research Center of Xiamen University, Xiamen, 361102, China.
一种新的ALK抑制剂WZH-15-125及其PROTAC衍生物WZH-17-002克服了ALK阳性非小细胞肺癌的耐药性. WZH-17-002有效降解ALK蛋白,并在临床前模型中显示出优异的疗效.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 药物发现 药物发现 药物发现
背景情况:
- 先进的一代ALK氨酸激酶抑制剂 (TKIs) 在ALK重组的非小细胞肺癌 (NSCLC) 中表现出成功.
- 在ALK TKI治疗后获得的耐药性突变是一个重大的临床挑战.
- 像G1202R/L1196M这样的特定突变使得对现有疗法,包括洛拉提尼布,产生耐药性.
研究的目的:
- 为了确定能够克服获得耐药性突变的新型ALK抑制剂.
- 设计和评估一种针对蛋白质溶解的奇米拉分子 (PROTAC) 以提高ALK降解.
- 在ALK驱动NSCLC的临床前模型中评估新型化合物的疗效.
主要方法:
- 鉴定和描述WZH-15-125作为一种强大的ALK抑制剂.
- 设计和合成WZH-17-002,一个针对ALK的PROTAC分子,使用WZH-15-125作为弹头.
- 通过WZH-17-002进行ALK蛋白降解的体外评估,包括确定DC50值.
- 使用异种移植小鼠模型进行体内疗效研究,这些小鼠模型含有特定的ALK抗性突变.
主要成果:
- WZH-15-125显示出强大的ALK抑制,包括像G1202R/L1196M这样的耐药性突变.
- WZH-17-002有效降解了ALK蛋白质,其DC50为25nM.
- 在相关模型中,WZH-17-002抑制了耐药性的出现,并且在体内表现出比lorlatinib更高的疗效.
结论:
- WZH-15-125及其PROTAC衍生物WZH-17-002代表了针对ALK重组的获得性耐药性NSCLC的有前途的治疗策略.
- 开发的ALK PROTAC分子提供了一种潜在的方法来克服具有挑战性的耐药性突变,包括对洛拉提尼布耐药的突变.
- 这些发现支持进一步开发WZH-17-002用于治疗耐火ALK驱动NSCLC的临床应用.
更多相关视频
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
09:38Establishment and Characterization of Three Afatinib-resistant Lung Adenocarcinoma PC-9 Cell Lines Developed with Increasing Doses of Afatinib
Published on: June 26, 2019
相关概念视频
Nitriles to Amines: LiAlH4 Reduction
As shown below, the mechanism involves three steps. Firstly, the hydride ion acting as a nucleophile attacks the nitrile carbon to form an anion. In the second step, a second equivalent of the hydride ion attacks the anion to...
Preparation of Amines: Reductive Amination of Aldehydes and Ketones
Combined Effects of Drugs: Antagonism
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
Enhanced Elimination of Poison
Antidotes serve a crucial role in counteracting the effects of poison by inhibiting enzymes responsible for producing harmful drug metabolites. In some cases, these toxic metabolites can be neutralized by endogenous cosubstrates, which are maintained at specific concentrations to prevent interaction with cellular macromolecules and subsequent cell death.
Renal excretion is the...
Phase I Reactions: Reductive Reactions
Anthelminthic Agents
